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ABSTRACT 
Recombinant protein expression is essential to biotechnology and 
molecular medicine, but facile methods for obtaining significant quantities 
of folded and functional protein in mammalian cell culture have been 
lacking. Here I describe a novel 37-nucleotide in vitro selected sequence 
that promotes unusually high transgene expression in a vaccinia driven 
cytoplasmic expression system. Vectors carrying this sequence in a 
monocistronic reporter plasmid produce >1,000-fold more protein than 
equivalent vectors with conventional vaccinia promoters. Initial 
mechanistic studies indicate that high protein expression results from dual 
activity that impacts both transcription and translation. I suggest that this 
motif represents a powerful new tool in vaccinia-based protein expression 
and vaccine development technology. 
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Chapter 1  
INTRODUCTION 
 
1.1 EUKARYOTIC TRANSLATION INITIATION 
Overview of Eukaryotic Translation 
The translation of mRNA transcripts into protein in eukaryotes is a 
multi-step process consisting of four main stages: (1) initiation, in which 
the ribosome, methionyl tRNA and other necessary factors assemble onto 
the mRNA start codon, (2) elongation of the peptide strand via the natural 
peptidyl transferase activity of the ribosome, (3) termination of the 
translated message and release of the protein, and (4) recycling of the 
translation machinery by disassembly of the mRNA-ribosome complex.1 
Of the four steps, most translational regulation occurs at initiation, 
underscoring the importance of understanding the factors that control 
ribosomal recruitment and translation initiation.1  
Gene regulation via translation control is advantageous because it can 
provide a faster phenotypic change than regulation at the transcription 
level because the mRNA is already made and ready to be translated.1 
Genome-wide translation regulation can be achieved by adjusting the 
availability of eukaryotic initiation factors (eIFs), poly(A) binding protein 
(PABP) or other species required for initiation.1,2 The translation of 
individual mRNAs can be controlled through interaction with microRNAs 
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(miRNAs), secondary structures in the 5’ UTR, open reading frames 
(ORF) upstream of the actual start codon and the context of the AUG start 
site (i.e. Kozak sequence).1,2 
Efforts to understand eukaryotic translation have revealed that 
translation initiation requires the coordination of many factors. The form 
and function of initiation factors continue to be discovered. Furthermore, 
recent additions to this growing body of knowledge expose a gap in our 
understanding of this complex process and all of the dynamic components 
that contribute to initiation. Here, I provide a review of canonical eukaryotic 
translation initiation and highlight some nontraditional mechanisms and 
unanswered questions. 
 
Translation Initiation 
The overall process of eukaryotic translation initiation is depicted in 
Figure 1. The current understanding of the canonical process of eukaryotic 
translation initiation begins with eukaryotic initiation factor (eIF) 2-GTP 
joining with a charged initiator tRNA (Met-tRNAi) to form the ternary 
complex (TC).3 Each round of translation initiation results in the release of 
eIF2-GDP that must be recycled to eIF2-GTP for the next round of 
initiation. eIF2 has a higher affinity for GDP than GTP so the exchange is 
assisted by eIF2B.4 The TC and the 40S ribosomal subunit (to which is 
bound eIFs 1, 1A, 3 and possibly 5) are brought together by eIF3 (a multi-
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domain protein responsible for binding several key players in translation 
initiation) to form the 43S pre-initiation complex (PIC)2,5 A capped, 
polyadenylated mRNA strand is prepared to receive the 43S PIC by the 
eIF4F complex (consisting of the ATP dependant RNA helicase eIF4A, the 
cap binding protein eIF4E and the scaffold protein eIF4G).6 eIF4E binds to 
the 5’ cap, bringing the eIF4F complex and the mRNA strand together.6 
EIF4B also binds the mRNA strand and plays a non-essential role 
assisting the RNA binding and helicase activity of eIF4A.7 The poly(A) 
binding protein (PABP) binds to the 3’ poly(A) tail of the mRNA strand and 
interacts with eIF4G as well, causing the mRNA to form a loop. This 
interaction increases the affinity of eIF4F for the cap and prevents mRNAs 
with truncated or degraded 3’ ends from being translated.8,9 The 43S 
complex loads onto the mRNA sequence near the 5’cap through 
interactions between eIF3 and eIF4G.10 The ribosome then begins to scan 
the mRNA searching nucleotide triplets for the AUG start codon with the 
help of several initiation factors.11,12 EIF4A unwinds RNA secondary 
structure13 and eIFs 1 and 1A aid scanning and correct initiation codon 
selection by blocking the A site of the ribosome until the correct codon in a 
favorable context is reached.14 Translation generally initiates at the first 
AUG codon in the 5’ region of a mRNA message with a few established 
exceptions: 1) when the first AUG is too close to the cap,15 2) when the 
AUG is in an unfavorable (non-Kozak) sequence context and is bypassed  
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Figure 1: Eukaryotic Translation Initiation.  I. eIF2B mediates the 
exchange of GDP for GTP in eIF2.4 eIF2-GTP binds Met-tRNAiMet to form 
the ternary complex (TC).3 II. The 40S ribosomal subunit, with eIFs 1, 1A, 
3 and possibly 5 bind the TC forming the 43S complex.5 III. Meanwhile, 
eIF4F complex composed of the subunits eIF4E, eIF4A and eIF4G binds 
to the 5’ m7G cap of an mRNA message with the help of the RNA binding 
protein eIF4B.  eIF4G also interacts with Poly A Binding Protein (PABP) 
bound to the 3’ poly A tail, causing the mRNA to form a circle.6 IV. The 
43S complex loads onto the mRNA near the 5’ cap through interactions 
between eIF3 and eIF4G.6 V. The complex scans the mRNA checking 
successive nucleotide triplets against the Met-tRNAiMet anticodon for the 
complementary AUG start codon.11, 12 Upon reaching the start codon, 
eIF2-GTP hydrolyzes to eIF2-GDP. VI. Hydrolysis of eIF2-GTP and 
binding of the 60S subunit, assisted by eIF5B-GTP, triggers the release of 
eIFs 1, 2, 3, 4B, 4F and probably 5.  eIF2-GDP is recycled to start another 
round.17, 18 VII. eIF5B-GTP hydrolyzes and is released with eIF1A.17 The 
80S complex is ready for elongation. 
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through leaky scanning, and 3) when the ribosome translates a short open 
reading frame, remains associated with the mRNA and reinitiates 
translation at a downstream AUG .11 Once an AUG pairs correctly with the 
anti-codon on the methionine tRNA the GTPase activating protein eIF5 
accelerates the hydrolysis of eIF2-GTP to eIF2-GDP.16 At this point eIFs 
1, 3, 4B, 4F, 5, and 2-GDP dissociate from the mRNA-ribosome complex 
while eIF5B-GTP binds along with the 60S ribosomal subunit.17,18 The 
binding of the larger subunit causes hydrolysis of eIF5B-GTP to eIF5B-
GDP, which then dissociates along with eIF1A.19 The ribosome is now 
positioned to receive charged tRNA and begin the process of elongation.   
 The study of several non-canonical variations of translation 
initiation is contributing to a greater understanding of the molecular origin 
of disease and the regulation of protein expression. One such mechanism 
is ribosomal “shunting.” First described in viral mRNA transcripts, shunting 
is a process whereby the 43S complex is able to temporarily disassociate 
from the mRNA and re-associate and initiate translation at a location 
further downstream.20 There is evidence that shunting also occurs in 
uninfected eukaryotic cells and may contribute to the dysregulation of 
protein expression in Alzheimer patients.21 The shunting model offers a 
possible explanation for the cap-dependent initiation of translation at a 
start site downstream of an AUG codon in “good” context or when the 5’ 
UTR of a mRNA strand contains a stable secondary structure that is 
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bypassed in order to reach a down stream initiation site.22,23 The shunting 
activity is mediated by sequences within the 5’UTR that are 
complementary to and interact with the 18S ribosomal subunit.24,25 An 
additional explanation of these phenomena is the “tethering and 
clustering” model proposed by Mauro and colleagues.26 In this model, the 
43S complex is “tethered” through the cap binding proteins to the mRNA 
strand that is able to fold over and allow the complex to interact with 
sequences complementary to the 18S ribosome, thereby bypassing any 
intervening secondary structure or AUGs.26 
 Transcripts containing an Internal Ribosomal Entry Site (IRES) are 
able to forego scanning and cap dependant translation by recruiting the 
40S ribosomal pre-initiation complex directly to the 5’UTR.27,28 IRES 
sequences were also first discovered in viruses that lack proteins 
responsible for adding a 5’ cap to the RNA message.29 Viral IRESs 
function by folding into large tertiary structures that mimic some or all of 
the eukaryotic initiation factors and in doing so are able to recruit the 
ribosome to the initiation site (see Figure 2).28 The picornavirus family, 
including encephalomyocarditis virus (EMCV), poliovirus and foot and 
mouth disease virus, contain secondary structures that bind eIF4G directly 
and do not require the cap binding protein eIF4E.30,31 The Hepatitis C 
Virus avoids using any part of the eIF4F complex or eIF4B through 
contacts with the stem loop structures of the IRES and the 40S  
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Figure 2: Capped mRNA and viral mRNA ribosome recruitment strategies. 
Comparison of canonical eukaryotic cap-dependent translation initiation 
(a) and the internal initiation mechanism used by the picornavirus 
encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES) 
(b), hepatitis C virus (HCV) IRES (c) and the cricket paralysis virus (CrPV) 
IRES (d). Reprinted (adapted in part or whole) with permission from 
Nature Reviews Microbiology (2008).27 
 
ribosome.32 The cricket paralysis virus (CrPV) IRES dispenses with the 
need for any initiation factors, including eIF2, or for the initiator tRNA by 
interacting directly with the 40S subunit and using a GCU codon to begin 
translation.28 IRESs have also been discovered in eukaryotic cells and 
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have been shown to direct expression of essential genes during 
starvation, cellular stress or conditions when regular protein production is 
shut down through the lack of initiation factors.33,34 
 
Unanswered Questions 
 Despite the advances that have been made in the understanding of 
eukaryotic translation initiation, there are still many unanswered questions. 
For instance, it has recently been discovered that the vast majority of the 
genome is transcribed but only a small percentage (<2%) is annotated as 
protein coding.35,36 Among these non-coding transcripts, researchers have 
identified a new class of RNAs termed long intergenic non-coding RNA 
(lincRNA). LincRNA are defined as transcripts greater than 200 bases that 
have no potential to be translated by the canonical translation initiation 
mechanism.37 However, the transcription of many of these sequences is 
highly regulated and there is evidence lincRNAs play important roles in 
development and cell differentiation.37 The polished rice (pri) transcript 
from Drosophila was considered to be non-coding because it contained 
only short open reading frames.38 In fact, pri mRNA codes for four very 
small peptides, between 11 to 32 amino acids, that play a pivotal role in 
the development of trichomes on Drosophila larvae.38 This discovery 
raises the possibility that other non-canonical peptides may be hidden in 
“non-coding” transcripts.  
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Alternative methods for initiation, such as IRESs, still require further 
investigation. Though the existence of IRESs in viral genomes is well 
established, the discovery and characterization of these elements in cells 
is still in the early stages. Recently, there has been a great deal of 
conflicting evidence qualifying or completely discrediting supposed cellular 
IRESs. A common assay to identify IRESs places the potential sequence 
in the intergenic region of a bicistronic plasmid. If the second gene is able 
to be expressed when the canonical translation initiation of the first gene is 
inhibited, it is assumed that the sequence mediated an internal translation 
initiation event. This assay for identifying IRES sequences was proved to 
be flawed by a series of studies showing that often the protein produced 
from the second gene may actually be attributed to cryptic promoter 
activity or poor experimental design.39–42 The validity of cellular IRESs 
needs to be solidified by requiring sequences to pass rigorous, well 
designed tests before being identified as IRESs. Such tests could include 
direct transfections of RNA containing the candidate IRES into cells. Direct 
RNA transfections bypass the nucleus and the potential splicing and 
mRNA modifications that take place there. These studies should also 
include structural analysis of the mRNA post-expression to ensure it is 
fully intact. These tests will help to rule out the possibility of transcriptional 
or nuclear processing artifacts, such as splicing, contributing to increased 
protein production.39,41 
	  
10	  
The mechanisms for regulating the translation initiation of individual 
mRNAs almost invariably inhibit initiation. These inhibitory mechanisms 
include miRNA, RNA binding proteins, RNA secondary structures in the 
5’UTR and, under most conditions, upstream Open Reading Frames.1,2,43 
The many pathways for translational suppression lead to the question: Is 
there a mechanism to enhance the translation initiation of individual 
mRNA strands, and if so could this mechanism depend on the presence of 
an mRNA sequence element? An element dependent mechanism could 
enable a cell to quickly produce a large amount of protein without having 
to repeatedly go through the energetically expensive and time-consuming 
processes of mRNA transcription and maturation. An example of a small 
sequence capable of enhancing translation when placed in the 5’UTR of a 
gene was discovered in the mouse genome.44 This sequence was shown 
to function through complementary base pairing with the 18S ribosome.45 
 
1.2 RECOMBINANT MAMMALIAN PROTEIN EXPRESSION SYSTEMS 
Proteins are macromolecular structures in living cells that have 
diverse roles from enzyme catalysts to receptors of extracellular signals, 
transducers of intracellular signals, and structural scaffolds. These diverse 
functions make proteins useful tools in molecular medicine, biotechnology, 
industry and agriculture. Although many systems have been developed for 
producing recombinant proteins, the ability to manufacture human proteins 
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with correct post-translational modifications (PTM) has remained 
challenging. In general, human proteins with correct patterns of PTMs are 
produced expensively and in low yields, which is cost prohibitive for many 
basic and applied research projects.46 Here, I briefly review the most 
commonly used expression systems and discuss their advantages and 
disadvantages. 
 
Bacterial Expression Systems 
Bacterial expression systems rely principally on the E. coli and 
related Bacillus species for heterologous protein expression. In these 
systems, the gene of interest is placed downstream of a regulated 
promoter on a plasmid that is transformed into the bacterial cell for high 
and controlled expression.47 
Bacterial systems have the advantage of being inexpensive to 
maintain, safe to use, easy to manipulate, and producing large quantities 
of recombinant protein.47 There are many limitations to bacterial 
expression systems as well. Disadvantages of this system include an 
inability to produce large mammalian proteins as well as PTMs such as 
glycosylation that are often essential for proper function.48 In some cases, 
high production yields can become problematic as overproduction can 
lead to cellular toxicity (an issue which can be addressed with specially 
engineered strains and growth conditions).49 Proteins produced in an E. 
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coli system are often packaged in inclusion bodies and require further 
processing for proper folding and activity.48 In addition, care must be taken 
when isolating the protein to remove any toxins produced by the bacteria. 
Thus, bacterial systems are the system of choice when manufacturing 
small (<30 kD), unmodified proteins, but are incapable of producing large 
proteins with complex PTMs.46 
 
Yeast Expression Systems 
Yeast is engineered to produce recombinant proteins by 
transformation with a plasmid containing the gene of interest. Once inside 
the cell, the plasmid can either be maintained as an episome or 
incorporated into the genome through homologous recombination, 
depending on the experimental design.50 The most common yeast species 
used for protein expression is S. cerevisiae, which has a well 
characterized eukaryotic genome.50  
Relative to E. coli systems, yeast systems produce less protein, but 
can produce large functional proteins with many common PTMs.48 Yeast 
can also be grown in defined, protein free media. This facilitates the 
purification of the recombinant protein and makes yeast culture more 
affordable than insect or mammalian cell culture.46  
Yeast systems can produce glycosylated proteins, but their pattern 
of PTMs is often different than the patterns found in proteins produced in 
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mammalian systems. For example, S. cerevisiae produces O-linked 
oligosaccharides with mannose while mammalian proteins have sialylated 
O-linked oligosaccharides. Yeasts also lack proper chaperonins that are 
required to properly fold some complex mammalian proteins.46 Though the 
glycosylation and folding abilities of yeast systems surpass those of 
bacterial systems, they are still insufficient for producing many mammalian 
proteins. 
 
Baculovirus Expression Systems 
Insect cells represent an attractive host for recombinant protein 
expression because of their capacity to produce proteins with folding and 
PTMs that are similar to proteins produced in mammalian cells.51 In the 
baculovirus system, the insect virus is engineered to contain the desired 
protein in place of a nonessential, highly expressed native gene. Insect 
cells (usually fall army worm cell lines Sf9 or Sf21) are then infected with 
the aculovirus and produce the protein.52 Recombinant baculoviruses 
were traditionally produced through homologous recombination with a 
transfer vector, which occurred at a low rate and required time-consuming 
plaque purifications. Bacmid technology streamlines this process by 
putting the baculovirus genome into a linearized bacterial artificial 
chromosome that is deficient in an essential gene. Homologous 
recombination with a transfer vector in an E. coli cell adds the recombinant  
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Figure 3: Baculovirus expression vectors over time. Various methods exist 
to generate recombinant baculoviruses expressing a foreign gene (gene 
X). Historically, recombinant baculoviruses were generated through 
homologous recombination (A). Subsequently, linearized vectors were 
developed to increase the percentage of recombinants, as an essential 
gene, orf1629, will be restored only upon recombination (B). Bacmid 
technology is based on transposition of gene X into a bacterial artificial 
chromosome containing the baculovirus genome and which is amplified 
and manipulated in E. coli (C). Bacmid technology and the repair of an 
essential gene were combined to avoid bacterial sequences in the virus 
genome and further automated (flashback/BacMagic) for high-throughput 
recombinant virus generation (D). Reprinted with permission (adapted in 
whole or part from J. Inv. Path. (2011).51 
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protein and restores the essential gene resulting in improved 
recombination frequency and removing the need for plaque purification.51  
Cultivation of insect cells also has the advantage of being more 
affordable and producing more product than mammalian cells.48 The virus 
is extremely safe to work with because it is incapable of infecting 
vertebrate cells and as such poses no danger to humans.51 However, the 
system does have drawbacks, including the technical challenges of 
building the recombinant virus. The baculovirus infection can impair 
protein processing, folding, secretion, and also results in high protease 
activity at the lytic stage of the viral life cycle.52,53 While the baculovirus 
system produces more protein than mammalian cell culture systems it still 
has relatively low yields compared to bacterial or yeast systems. There 
are also differences between the PTMs of some baculovirus produced 
proteins and their mammalian counterparts that cause the baculovirus 
proteins to be inactive.54,55 
 
Mammalian Cell Culture Expression Systems 
 Mammalian cell culture systems are necessary to produce proteins 
that require mammalian-specific PTMs in order to achieve functional 
activity.48 Mammalian cell based expression systems are either plasmid or 
virus based.  
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Plasmid based systems 
Under transient transfection conditions, plasmids containing the 
gene of interest under the control of a strong transcription promoter are 
transformed into the cells using calcium phosphate transfection, 
electroporation or lipofection methods.56 Protein is harvested from the 
cells 1-10 days post transfection.57  
Protein can also be expressed by creating a stably transfected cell 
line, although this process is considerably more difficult and can take 
several months to achieve. A typical stable transfection protocol requires 
transforming cells with both the gene of interest and a gene that confers a 
selective advantage such as antibiotic resistance. A small percentage of 
foreign DNA will enter the nucleus and integrate into the cell genome. 
Applying a selective pressure reduces the cell population so that it only 
contains members that were successfully transformed. Individual cells are 
then grown and evaluated for protein production. A colony of cells will be 
selected to found a cell line based on protein production levels and growth 
characteristics.56  
Virus based systems 
Adenoviruses can infect a diverse range of human cells and 
replicate with high efficiency, making them good candidates for expression 
of mammalian genes.58 Adenoviruses engineered for recombinant protein 
expression are replication incompetent outside of suitable complementing 
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cells to increase the safety profile. There are two methods used to 
generate recombinant adenovirus. The first requires transfecting a shuttle 
vector carrying the gene of interest into complementing cells that have 
been infected with adenovirus. Homologous recombination places the 
gene of interest into the viral genome under control of an early promoter 
and the complementing host cell enables viral replication. Successive 
screening and plaque purifications identify and purify the desired 
recombinant virus. In an alternative method for producing recombinant 
adenovirus, homologous recombination takes place inside E. coli cells 
between a shuttle vector and a vector containing the adenovirus genome. 
Once the desired adenovirus is created, it is infected into (non-
complementing) host cells where it enters the nucleus but does not 
integrate into the genome and the cell transiently produces the 
recombinant protein.58,59  
Lentivirus is a retrovirus that integrates its genome into that of the 
host cell and is used for generating cell lines that stably produce 
recombinant proteins. Lentivirus has the additional advantage of being 
able to infect non-replicating cells. The lentivirus system is very similar to 
the adenovirus system in that virus used for protein expression is 
engineered to be replication incompetent without the help of a packaging 
system. Homologous recombination between the modified lentivirus and a 
transfer cassette containing the gene of interest takes place in a  
	  
18	  
Table 1: Comparison of Mammalian Protein Expression Systems 
Expression 
System 
System 
Construction 
Time 
Expression 
Time 
Advantages Disadvantages 
E. coli Days Hours Simple 
technology 
High yields 
Safe 
Fast 
Affordable 
Incapable of 
producing 
large proteins 
or PTMs 
Inclusion 
bodies, require 
purification 
and 
renaturation 
Yeast Days ≤ 1 day Simple 
technology 
High yields 
Safe 
Fast 
Affordable 
Glycosylation 
Differences in 
glycosylation 
patterns 
Mammalian 
specific PTMs 
Improper 
folding 
Baculovirus Weeks to 
months 
1-several 
days 
Good yields 
Safe 
Many 
mammalian-
like PTMs 
Advanced 
technology 
Time 
consuming 
Cannot 
produce all 
mammalian 
PTMs 
Mammalian 
cell: 
Transient 
transfection 
Weeks 1-several 
days 
Safe 
Mammalian 
PTMs 
Low yields 
Expensive 
Mammalian 
cell: Stable 
transfection 
Months 1-several 
days 
Safe 
Mammalian 
PTMs 
Low yields 
Time 
consuming 
Expensive 
Mammalian 
cell: Viral 
systems 
(Adenovirus 
and 
Lentivirus) 
Weeks to 
months 
1-several 
days 
Mammalian 
PTMs 
Better yields 
than plasmid 
based 
systems 
Safety 
Time 
consuming 
Relatively low 
yields 
Expensive 
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packaging cell containing vectors that provide the viral proteins necessary 
for replication.60 Recombinant lentivirus conveniently integrates the gene 
of interest along with a promoter sequence into the host genome, 
generating a stably transfected cell line. 
The vaccinia virus system, which is also used to express 
recombinant proteins, is described elsewhere in this manuscript. 
While viral systems are efficient and generally produce more 
protein than their plasmid based counterparts, they have the disadvantage 
of being potentially hazardous to the humans who work with them. Care 
must also be taken to prevent contamination of the final protein product 
with virus as well.46 In addition, generating a new recombinant virus for 
every protein is time consuming and expensive. 
 Thus, although recombinant proteins from mammalian cell culture 
systems are correctly folded and modified, their production requires an 
expensive investment of time and money for a relatively low yield, which 
discourages their use unless necessary for function. 
 
1.3 VACCINIA VIRUS REVIEW 
Basic Vaccinia Biology 
Vaccinia viruses (VVs) belong to the family Poxviridae and genus 
Orthopoxvirus.61 This genus also contains variola virus, the causative 
agent of smallpox. VVs are DNA viruses with large, double stranded linear 
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genomes ranging in size between 178-192 kb, depending on the strain.62 
Such a large genome is required because VVs carry all the genes 
necessary for DNA transcription and viral replication to occur in the 
cytoplasm.61 Each viral particle also comes packaged with all the enzymes 
necessary for the transcription and maturation of viral RNA.63  
Virus can enter the body through a break in the skin and manifests 
as a localized lesion.61 Upon viral entry into a cell, early promoters direct 
the expression of proteins that block the body’s extracellular and 
intracellular antiviral defenses.64 Proteins for DNA replication and 
transcription are also made early in the viral life cycle.64 Genes that are 
expressed at an intermediate time point in the viral life cycle produce 
transcription factors for late genes expressed at the end of the viral life 
cycle prior to cell lysis. Late genes include proteins necessary for virion 
assembly.64 VVs are also capable of infecting a wide range of cultured 
mammalian cells. In cultured cells, DNA replication has been observed as 
early as 1-2 hours post infection, with new virus produced in 8 hours.64 
 There are four VV virion types that play different roles in the spread 
of infection. Intracellular mature viruses (IMV) are released after lysis and 
are responsible for host-to-host transmission. Intracellular enveloped virus 
(IEV) fuses with the cell membrane to form cell-associated enveloped 
virus (CEV), which mediate the spread of infection to neighboring cells.  
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The virus is spread to distant cells in the same host or cell culture by 
extracellular envelope virus (EEV).64  
 
History of the VV Smallpox Vaccine 
Vaccine technology was pioneered by Edward Jenner over 200 
years ago when he began exposing people to a milder member of the 
poxvirus family to prevent infection with the more virulent and potentially 
lethal smallpox.65 Because of the high conservation between all members 
of the orthopoxvirus genus, exposure to a VV also serves to vaccinate 
against variola virus.65 Jenner originally used cowpox virus as a vaccine, 
but over years of use, experimentation and poor record keeping a related 
but genetically distinct virus emerged and consequently the exact origin of 
VV is unknown.61 The effectiveness of the vaccine, coupled with the fact 
that humans are the only known reservoir and do not carry an 
asymptomatic form of smallpox, encouraged the worldwide campaign to 
eradicate this disease.61 Global elimination of smallpox was achieved in 
1980 through widespread vaccination, strict surveillance, and quarantine 
programs.61 Interest in VVs remains high due to their potential use as 
vaccines for other diseases, their utilization in mammalian expression 
systems, and due to the fear of accidental or malicious reintroduction of 
smallpox.66 
 
	  
22	  
Potential for Recombinant VV Vacines 
Given the success of vaccinia in ridding the world of smallpox, 
researchers are developing the technology to use VV as a vehicle to 
introduce antigens of other diseases to the immune system.65 The large 
genome and high productivity of VVs make them an ideal recombinant 
system for incorporating and expressing foreign proteins (Figure 4).57 VV 
vectors have been reported to incorporate at least 25 kb of foreign DNA.67 
However, there are still concerns about the safety of VV. There are rare 
cases of severe and even lethal reactions to the vaccine, mostly among 
immunocompromised recipients.65 In an effort to attenuate VV, viral strains 
that are incapable of replicating in human cells have been developed.68 
These include the modified vaccinia virus Ankara (MVA) strain, which can 
infect but not replicate in human cells. MVA is also made less virulent by 
the loss of genes involved in evading the host immune system.62 
Unfortunately, these attenuated strains tend to make less effective 
vaccines that cannot generate an immune response strong enough for 
vaccination.65 Strategies to create vaccines that are both safe and 
effective include co-expressing immune modulators with attenuated 
vaccines and deletion of virulent genes from more dangerous viruses.69,70 
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Figure 4: Formation of a recombinant vaccinia virus by homologous 
recombination. Reprinted with permission from Science (1991).63 
 
VV Expression Systems 
In order to produce proteins with proper folding and post 
translational modifications that are suitable for human therapeutics, a 
mammalian cell based system is required.71 VV is particularly well suited 
for heterologous protein expression because transcription occurs in the 
cytoplasm, thereby eliminating the possibility of interference from nuclear 
splicing or mRNA transport. VV also has a wide host range and can infect 
most cultured mammalian cells.71 The vTF7-3 strain has been modified to 
contain the bacteriophage T7 RNA polymerase specifically for 
recombinant protein expression.72 The gene of interest, along with a T7 
promoter, can be incorporated into the viral genome through homologous 
recombination or engineered onto a plasmid and transfected into cells that 
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are subsequently infected with the virus.72–74 VV expression systems can 
produce more protein than standard stable transfections of mammalian 
cells and have the potential to be used in large-scale bioreactors.75 
Bleckwenn et al reported a yield of ~12 µg EGFP/million infected cells in a 
vaccinia bioreactor system.75 Because it is a safety concern to work with 
VV, most vaccinia strains require Biosafety Level 2 (BSL2) procedures 
and vaccination is recommended for personnel at risk for exposure.71 The 
potential for infection can be lessened or removed by using attenuated 
strains such as MVA, which can be used under BSL1 conditions.68,73 
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Chapter 2 
CHARACTERIZIATION OF A SEQUENCE THAT FUNCTIONS AS A 
TRANSLATION ENHANCER AND VV PROMOTER 
 
2.1 CONTRIBUTIONS 
 The following chapter describes the discovery and characterization 
of a sequence element that works as both a VV promoter and a translation 
enhancer. The project was conceived by Professor John Chaput. The 
reported experiments were performed by Julia Flores, Brian Wellensiek 
and Brett Stephens under the guidance of John Chaput. Brian Wellensiek 
performed the mRNA display selection and Brett Stephens did the initial 
characterization and preliminary end mapping deletion analysis of the Best 
sequence. Julia Flores finished the end mapping deletion analysis and ran 
the western blots, realtime PCR, DNA analysis, RACE, and time course 
experiments with assistance from Brian Wellensiek. John Chaput wrote 
the manuscript with comments from Julia Flores and Brian Wellensiek. 
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2.2 INTRODUCTION 
Vaccinia virus (VV), a member of the poxvirus family, received 
worldwide attention when it was used to eradicate variola virus, the 
causative agent of smallpox.65 Since then, poxviruses have been 
engineered for other biomedical and biotechnology purposes, which 
includes their use as a vehicle for protein expression in mammalian cell 
culture and as a vector for therapeutic vaccines directed against infectious 
agents and cancer.63 The interest in poxvirus technology is due to a 
number of unique properties that are not found in other DNA viruses. 
Principal among these is the ability for poxviruses to replicate in the 
cytoplasm of their host cell, which avoids many of the complications 
associated with RNA splicing and export.76 Poxviruses can infect a wide 
range of host cells and produce gene products with mammalian patterns 
of post-translational modifications (PTMs).73 Non-mammalian systems can 
produce proteins with alternative modifications, which is problematic if 
these proteins are to be used as therapeutics, as targets in drug-based 
screens or as antigens for antibody production.77,78 
It is known that recombinant vaccinia viruses are capable of 
producing milligram quantities of protein in mammalian cells.73 However, 
these viruses require special expertise to construct and are therefore not 
suitable as a general platform for routine expression needs. Whether 
similar expression levels can be achieved in a transient transfect-infect 
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assay is an interesting question with significant practical implications in 
many areas of basic and applied research.46  
We postulated that it might be possible to improve protein 
expression levels in mammalian cells if TEEs could be identified that 
effectively engaged the translation machinery. From a screen of ~250 in 
vitro selected sequences, we identified a short (37-nt) motif that is capable 
of achieving unusually strong transgene expression in a wide range of VV 
infected mammalian cells. Relative to the recombinant T7 vaccinia 
expression system, our system can produce >100-fold more protein after 
6-12 hours of transient expression and >10,000-fold more protein when 
compared to other expression systems.72 
 
2.3 MATERIALS AND METHODS 
Cell Culture 
All cells used in this study were obtained from the American Type 
Culture Collection (ATCC). HeLa and HEK293 cells were maintained in 
DMEM (Invitrogen), while BHK cells were maintained in MEM (Invitrogen). 
All media was supplemented with 5% fetal bovine serum (FBS, HyClone) 
and 5 mg/ml gentamicin (Invitrogen). Cells were kept at 37°C in a 
humidified atmosphere containing 5% CO2. 
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VV Strains 
The Copenhagen and vTF7-3 viral strains used in this study were 
obtained from ATCC. The modified vaccinia virus Ankara (MVA) was from 
Sanofi Pasteur. The Copenhagen strain (VC2) is a wild type vaccinia 
virus,65 MVA is an attenuated vaccinia virus strain that is non-pathogenic 
in humans62 and vTF7-3 is a recombinant vaccinia virus strain that has 
been engineered to express T7 RNA polymerase.72 Viral stocks were 
stored in MEM with 2% FBS. 
 
Transfection/Infection 
Cells were seeded at a density of 15,000 cells per well in white 96-
well plates 18 hours prior to transfection (Figure 5). Plasmid transfections 
were carried out using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s protocol. In brief, complexes containing 200 ng of plasmid 
and 0.5 µl of Lipofectamine 2000 were formed in Opti-MEM (Invitrogen). 
During complex formation, DMEM was discarded from the 96-well plate, 
and 50 µl of fresh Opti-MEM were added to the cells. Complexes (50 µl) 
were then carefully overlaid onto the cells (total volume 100 µl). 
Immediately following DNA transfections, cells were infected with VC-2,  
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Figure 5: VV Transfect/Infect system. The luciferase gene was placed 
under the control of VV promoter SLP and transfected into cells that were 
infected with VV. Figure courtesy of Brian Wellensiek. 
 
MVA, or vTF7-3 at a multiplicity of infection (m.o.i.) of 5 plaque forming 
units (PFU)/cell for six hour assays or 30 PFU/cell for 24 hour assays. For 
protein isolation, HeLa cells were plated at a density of 200,000 cells per 
well in a 24 well plate and 800 ng of plasmid were combined with 2 µl of 
Lipofectamine 2000 to form the transfection complexes. Media was 
removed from the wells and 400 µl of Opti-MEM media were added to the 
cells, which were then overlaid with 100 µl of transfection complexes. 
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Luciferase Activity Assay 
Cells were lysed in the 96-well plate by discarding the growth-
transfection media and adding passive lysis buffer (Promega). Luciferase 
activity was measured using the Promega Luciferase Assay System 
according to the manufacturer’s protocol with a Glomax microplate 
luminometer (Promega). 
 
RNA Characterization 
RNA was isolated from transfected HeLa cells 6 hours post 
infection with VC2. Lysate from 2 wells of a 96 well plate were pooled and 
RNA isolation was performed using the PerfectPure RNA cultured cell kit 
(5 Prime) according to manufacturer’s protocol. Isolated RNA was reverse 
transcribed with an oligo (dT) primer and Superscript II (Invitrogen). 
Realtime PCR (iQTM SYBR® Green Supermix, Bio-Rad) was used to 
determine the mRNA levels of luciferase as well as the housekeeping 
gene hypoxanthine-guanine phospho-ribosyltransferase (HPRT). Using 
the ΔΔCt method, the amount of luciferase mRNA was normalized to 
HPRT mRNA levels. Luminescence values were adjusted according to 
normalized luciferase mRNA levels. 
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End Mapping Deletion Analysis 
Deletion analysis of HGL-Best was performed by Klenow extension 
of a short DNA primer annealed to the synthetic DNA templates containing 
BamHI and NcoI restriction sites. The double-stranded DNA was 
restriction digested and ligated into a monocistronic firefly luciferase 
reporter plasmid (F-luc-mono) carrying a vaccinia virus synthetic later 
promoter upstream of the insert (Wellensiek et al., manuscript in 
preparation). Reporter plasmids containing truncated variants of the Best 
sequence were assayed for activity in the vaccinia virus transfect-infect 
assay as described above. 
 
Western Blot 
Western blot analysis was performed using F-luc-mono engineered 
with six different leader sequences in the 5’ UTR (Best-core, SLP, SLP-
Best-core, I1L, I1L-Best-core, and a random filler sequence). A second set 
of plasmids were generated by replacing the luciferase gene with the gene 
for HIV-1 Gag. In all cases, proteins were expressed in a standard 
transfect-infect assay in HeLa cells for 6 hours and lysed with 35 µl of 
Passive Lysis Buffer (Promega). Cellular debris was removed by 
centrifugation at 10,000 rcf for 10 min and the supernatant containing the 
protein of interest was removed and stored at -80°C. For protein analysis, 
the supernant was diluted with NuPage 4x LDS sample buffer (Invitrogen) 
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and proteins were denatured by heating at 95°C for 10 min before being 
run on a NuPage 4-12% Bis-Tris gel (Invitrogen) at 200V for 30 min. 
Proteins were transferred to a nitrocellulose membrane using the iBlot Gel 
Transfer system (Invitrogen) using the manufacturers instructions. After 
blocking for one hour at room temperature in TBS-Tween (20 mM Tris, 
125 mM NaCl, pH 7.5, and 0.05% Tween) with 3% milk the membrane 
was cut along the 50 kDa band of a pre-stained protein ladder so that the 
protein of interest, either luciferase (66 kDa) or HIV-1 Gag (55 kDa), and 
the loading control, GAPDH (37 kDa) could be detected separately. The 
membrane pieces were incubated with the appropriate primary antibodies 
in TBS-Tween with 3% milk overnight at 4°C. The Firefly Luciferase and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies were 
obtained from Abcam while the HIV-1 Gag antibody was obtained from 
Professor Dr. Hohne at the Charite Institute for Biochemie in Berlin, 
Germany. Goat-anti-mouse or goat-anti-rabbit HRP conjugated secondary 
antibodies (Bethyl Laboratories) were then incubated with the membranes 
for one hour at room temperature. Membranes were visualized with 
SuperSignal West Pico or Dura Chemiluminescent Substrate (Pierce 
Biotechnology).   
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RACE 
RNA was isolated using the PerfectPure RNA cultured cell kit (5 
Prime) according to manufacturer’s protocol. Rapid amplification of cDNA 
ends (RACE) was performed with the 5’ RLM-RACE kit (Invitrogen) using 
total RNA following the small reaction protocol provided by the 
manufacturer with primers specific to the luciferase gene. RACE 
sequences were ligated into pJET 1.2 (Fermentas), cloned, and 
sequenced at the ASU DNA Sequencing Facility.  
 
DNA Isolation and Real Time PCR 
Cellular and plasmid DNA was isolated from transfected HeLa cells 
six hours post infection with VC2 using the Trizol Reagent (Invitrogen) 
according to the manufacturer’s protocol. Following isolation, DNA was 
ethanol precipitated and re-suspended in water. Quantitative realtime PCR 
(iQTM SYBR® Green Supermix, Bio-Rad) was used to determine the levels 
of plasmid DNA as well as the housekeeping gene Ribonuclease P 
(RNase P).79 Using the ΔΔCt method, the amount of plasmid DNA was 
normalized to RNase P DNA levels. 
 
Cell Free System 
Cell-free characterization was performed using a Human In vitro 
Protein Expression Kit (Pierce). Luciferase expression was achieved 
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following manufacturer’s protocols using 300 ng of linear template for a 
two-hour transcription at 32°C followed by a 90 min translation at 30°C. 
 
Primers 
Real Time PCR Primers 
Luciferase: 
 RTluc.F: 5’ GCTGGGCGTTAATCAGAGAG 
 RTluc.R: 5’ GTGTTCGTCTTCGTCCCAGT 
HPRT: 
 RThprt.F: 5’TGCTGAGGATTTGGAAAGGGTG 
 RThprt.R: 5’ CCTTGAGCACACAGAGGGCTAC 
RNase P: 
hRNaseP.F: 5’CCCCGTTCTCTGGGAACTC 
hRNaseP.R: 5’TGTATGAGACCACTCTTTCCCATA 
RACE Primers 
Luc30.R (Outer primer): 5’GTACGTGATGTTCACCTCGATATGTGCATC 
Dlpseq.R (Inner primer): 5’AGGAACCAGGGCGTATCTCT 
 
2.4 RESULTS 
We have previously used messenger RNA display to isolate RNA 
sequences from the human genome that function with TEE activity 
(Wellensiek et al., manuscript in preparation). After 6 rounds of in vitro 
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selection and amplification, an initial set of 1000 human genomic elements 
were cloned and sequenced. Of these, 227 mapped with perfect identity 
(length and sequence) to the human reference genome. Initial 
experimental characterization revealed that many of these sequences 
could enhance protein translation levels in a human cell-free expression 
system. This observation suggested that it might be possible to increase 
protein production levels in a mammalian cell culture using our selected 
TEEs to promote ribosomal initiation at the translation start site.  
To investigate this possibility, our set of 227 in vitro selected 
sequences were inserted into a firefly luciferase reporter plasmid (F-luc-
mono) containing a vaccinia-specific promoter (Fig 1a). Transfected HeLa 
cells were infected with VV (Copenhagen strain, 5 moi) and luciferase 
activity was measured in 96-well format after 6-hours of cell-based 
expression (Figure 5). Vectors carrying either a no-insert control or one of 
ten randomly chosen sequences from the starting library provided a basal 
level of translation enhancement and no infection controls were used to 
demonstrate that luciferase activity was the result of cytoplasmic 
translation and not a product of nuclear expression. Consistent with earlier 
in vitro assays, plasmids carrying the selected TEEs provided luciferase 
values that were up to 100-fold stronger than the basal translation level 
observed for the set of eleven control vectors (Figure 6). However, one 
sequence, HGL-Best, routinely yielded luciferase values that were as 
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much as 5,000-fold higher than the basal level, indicating that this 
sequence exhibited remarkable translation enhancement activity in a 
vaccinia driven cytoplasmic expression system (Figure 6b).  
To determine whether the high activity of HGL-Best was due to 
greater RNA expression or increased translation enhancement, 
quantitative real-time PCR was used to measure mRNA levels in cells 
expressing the HGL-Best containing vector. This analysis revealed that 
high luciferase activity was principally due to increased levels of 
expression; however, increased translation levels were also detected by 
normalizing luciferase activity values for cellular mRNA. When compared 
to the next highest activity sequences, HGL-Best produces ~10-fold  
 
Figure 6: Functional analysis of HGL-Best. (a) Schematic view of the 
luciferase reporter plasmid used to evaluate in vitro selected TEEs. (b-d) 
Firefly luciferase gene expression and translation of Best relative to four 
randomly chosen sequences from the original naïve pool (labeled round 
0), and the nine most active sequences discovered after six rounds of in 
vitro selection and amplification (labeled round 6) in vaccinia infected 
HeLa cells. Realtime quantitative PCR measurements coupled with 
chemiluminescence measurement indicate that Best functions as both a 
vaccinia promoter and translation enhancing element. This dual activity 
leads to a significant increase in luciferase production in vaccinia infected 
cells. 
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more RNA and ~5-fold more protein than all other plasmids tested (Figure 
6c,d). We confirmed by quantitative real-time PCR that plasmid copy 
number was not altered in cells transfected with the HGL-Best plasmid 
(Figure 7b), indicating that HGL-Best impacts gene expression at the 
levels of transcription and translation, but not replication. This unusual 
feature is not without precedent, and at least one other RNA element is 
known to function in this capacity albeit less efficiently.80  
We determined the minimal region required to achieve strong gene 
expression using end-mapping deletion analysis. Variants of HGL-Best 
were generated by primer extension using templates that contained 
incremental deletions from the 5' and 3' ends of the full-length 90-nt parent 
sequence. We compared luciferase activity values for each deletion 
construct to the parent sequence, which defined a core functional region 
of 37-nts spanning a boundary from residues 6-42 (Figure 7a). The core 
region is ~2-fold more active than the full-length sequence and substantial 
drops in activity were observed with additional deletions that extend into 
either end of this region. Because of its small size and high functional 
activity, we focused the remainder of our study on this 37-nt region of 
HGL-Best, which greatly simplified the engineering of recombinant 
expression vectors. 
Given the unusual ability for HGL-Best to enhance expression and 
translation, we decided to determine which nucleotides within the core  
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Figure 7: End Mapping Deletion Analysis. (a) Monocistronic constructs of 
the full-length HGL-Best (Best 1-90) and variations of this sequence were 
analyzed in a vaccinia transfect-infect luciferase reporter assay to identify 
the core functional domain of HGL-Best. Subscript labels indicate the 
nucleotide fragment analyzed for each HGL-Best construct. Translation 
activity is represented as a percentage relative to the full length HGL-Best 
sequence. The normalized percent error is shown in parenthesis. (b) Real 
time PCR analysis of plasmid DNA isolated from cells transfected with a 
HGL-Best or empty vector. Values were normalized to genomic DNA. (c) 
Luciferase RNA and protein levels produced by HGL-Best vectors with 
and without the SLP promoter. 
 
region were responsible for these two activities. Rapid amplification of 
cDNA ends (RACE) was performed on the 5' end of luciferase mRNA 
isolated from HeLa cells transfected with the HGL-Best plasmid and 
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infected with VV. DNA sequencing of the 5' RACE product revealed the 
presence of 11-nts from the 3' end of the HGL-Best core preceded by a 
short polyA tail (Data not shown). The short polyA tail is a post-
transcriptional modification that occurs as a result of VV expression. This 
result indicates that the first 26-nts of HGL-Best function as a VV 
promoter, while the last 11-nts function as a TEE. This prediction is 
supported by our deletion analysis study, which showed that removing 5-
nts from the 3' end of the core HGL-Best sequence reduced luciferase 
activity ~50%, while a further deletion of 10 or more nts abolished activity 
altogether. 
To confirm VV promoter activity of HGL-Best, we constructed a 
modified luciferase plasmid (F-luc-mono-Best) that removed the VV 
synthetic late promoter (SLP) from the vector. We then compared 
luciferase activities of HGL-Best to two well-established VV promoters, 
SLP and I1L. Comparisons were made for HGL-Best, SLP and I1L alone, 
and for HGL-Best in tandem with SLP and I1L in VV infected HeLa cells. 
After 6 hours of cytoplasmic expression, Western blot analysis indicated 
that vectors carrying HGL-Best, either alone or in tandem with SLP and 
I1L, produced substantial amounts of luciferase when compared to 
traditional SLP and I1L promoters (Figure 8). Prolonged exposure times 
with a more sensitive chemiluminescent substrate made it possible to 
visualize protein from the SLP construct, which appeared as a faint band  
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Figure 8: Comparative western blot analysis. The ability of the HGL-Best 
core region to enhance protein expression when placed in the 5’UTR of 
luciferase or the HIV gag protein was compared to the protein expression 
levels of vaccinia promoters SLP and I1L both alone and in combination 
with Best. HeLa cells were transfected with reporter plasmids and 
subsequently infected with vaccinia virus. Protein for western blots was 
harvested 6 hours post infection. Controls include protein from cells 
transfected with plasmid but not infected with virus and protein from 
untreated cells. 
 
relative to the HGL-Best generated product. This result is consist with our 
original screen, which indicated that HGL-Best produced ~5,000-fold more 
protein than an SLP containing vector lacking a human TEE. We verified 
that HGL-Best could promote high expression of biologically relevant 
proteins by replacing the luciferase gene in the F-luc-mono-Best vector 
with HIV Gag. Western blot analysis closely mirrored the luciferase 
expression profile, indicating that HGL-Best was likely capable of broad 
antigen tolerance (Figure 8).  
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 Recognizing the potential for HGL-Best as a general tool for 
mammalian protein expression, we compared luciferase expression 
profiles for HGL-Best to current state-of-the-art technology for vaccinia-
based expression. In this regard, the vaccinia T7-EMCV expression 
system is recognized as the most efficient protein production system for 
VV-based expression in mammalian cell culture.63 We therefore designed 
a control vector that contained an internal ribosomal entry site (IRES) from 
the encephalomyocarditis virus (EMCV) in place of HGL-Best. Two 
version of this vector were constructed; one that contained an SLP 
promoter for expression with the VV strains VC2 and MVA, and a second 
that contained the T7 promoter for expression in a recombinant VV 
expression system (vTF7-3) engineered to co-express T7 RNA 
polymerase. To facilitate a direct comparison of HGL-Best and EMCV in 
the recombinant T7 expression system, a modified version of F-luc-mono-
Best was constructed that contained the T7 promoter upstream of HGL-
Best.  
 An initial comparison was performed in HeLa cells for vectors 
carrying HGL-Best alone and in tandem with SLP and T7 to T7 EMCV and 
SLP EMCV. Expression profiles were monitored by time course analysis 
for cells infected with VC2, vTF7-3, and MVA (Figure 9). Relative to 
EMCV, the HGL-Best containing vectors each exhibit a rapid burst in 
protein production that saturates at 6 hours post-infection for VC2 and 12  
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Figure 9: VV time course in HeLa cells. HeLa cells were transfected with 
plasmid and infected with one of three VV strains (VC2, vTF7-3 or MVA) 
and we obtained a time course of their expression profiles. Luciferase 
levels were read at 3 hour intervals for the first 12 hours and at 6 hour 
intervals until 24 hours. Relative Light Units are reported. 
 
hours post-infection for vTF7-3 and MVA. Of the various HGL-Best 
vectors, the T7 modified version consistently produced ≥10-fold more 
luciferase after 24 hours of expression than HGL-Best either alone or in 
tandem with SLP. In comparison to EMCV, the HGL-Best vectors produce 
100-1,000 fold more protein after 6-12 hours of expression. Only after 24 
hours of expression is EMCV equivalent to HGL-Best alone and with SLP, 
which is still less efficient than the T7 HGL-Best vector.  
 
2.5 DISCUSSION 
The increasing need for recombinant mammalian proteins in 
medicine, agriculture and industry drives a continuous search for ways to 
improve the yield, quality and safety of recombinant expression systems. 
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Small, unmodified proteins can be produced quickly and cheaply using 
bacterial or yeast based systems but these organisms are incapable of 
generating mammalian PTMs that are sometimes crucial for activity.46 The 
baculovirus insect cell system is capable of producing many but not all 
mammalian PTMs and has the additional drawback of being a technically 
difficult system to develop.51 Only in mammalian cells can the complete 
set of correct PTMs be manufactured.48 However, these systems are 
notorious for producing low yields and being expensive to maintain. 
Transient transfection of DNA into mammalian cells is quick and simple 
but produces the lowest yields. While stably transfected cells can have 
higher yields, generating a stably transfected cell line is a complicated 
process that can take over a year.56 Very high protein levels have been 
reported from infecting cells with recombinant viruses engineered to 
produce the desired protein but once again, creating the recombinant virus 
can be a complex, time consuming process.  
A simpler variation of a virus based mammalian expression system 
involves transfecting cells with a plasmid and then infecting them with a 
VV that drives the transcription and translation of the protein in the 
cytoplasm. To use this system, all that is required is the creation of a 
plasmid with the gene of interest under the control of the appropriate 
promoter. Here, we describe the identification and characterization of 
sequence HGL-Best, which can improve protein yields from the VV 
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transfect/infect system by 10-fold when placed in the 5’ UTR of a gene. 
We determined that HGL-Best achieved this increase in protein production 
by acting both as a VV promoter (transcribing 10-fold more protein than 
standard promoters) and translation enhancer (producing 5-fold more 
protein than other plasmids tested when normalized to RNA levels). The 
promoter activity of HGL-Best was confirmed by its ability to perform 
equally well without a VV promoter.  
Translation enhancing elements often contain a shorter core 
sequence responsible for activity. We found through end mapping deletion 
analysis that the 90 nt HGL-Best has a core region only 37 nt long. RACE 
experiments revealed that the last 11 bases of the sequence are present 
on the 5’ end of the mRNA and suggests they are involved in translation 
enhancement, implying that the first 26 bases are responsible for promoter 
activity. The small size of the HGL-Best sequence is another advantage. 
Unlike EMCV and other IRES sequences used to promote translation 
initiation, which can be hundreds of bases long, HGL-Best is less than 50 
bases and can be easily inserted into plasmids. 
We considered the possibility that the high activity of HGL-Best is a 
phenomenon unique to luciferase, but western blot analysis of HIV Gag 
protein showed that the sequence could generate increased amounts of 
this protein as well. We isolated protein produced by plasmids containing 
the luciferase or HIV Gag gene under the control of HGL-Best or VV 
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promoters alone and in tandem with HGL-Best and found that only in the 
presence of HGL-Best were high levels of product detected. This 
demonstrates that the activity of HGL-Best is not protein specific and 
could be used to produce many different proteins, including those with 
complex PTMs. It has previously been shown that recombinant proteins 
produced in the VV system receive the appropriate mammalian PTMs, 
including glycosylation, phosphorylation, myristalation, folding and 
proteolytic cleavage.63 
In direct comparisons, HGL-Best is shown to outperform known VV 
promoters in all tested VV strains (VC2, MVA and vTF7-3) by producing 
higher titers of protein at earlier time points. A time course of HGL-Best 
protein levels revealed the expression profile and optimum expression 
time of the sequence. High levels of protein can be seen as early as 6 
hours post infection with the HGL-Best sequence alone whereas it takes 
24 hours for the standard system plasmid (T7/SLP-EMCV) to produce 
similar levels. Combining our sequence with the T7 promoter creates the 
most effective protein expression vector. T7 Best vector was ~50,000-fold 
more efficient with VC2 and ~1,000 fold more efficient with vTF-3 and 
MVA than the conventional plasmid at 6 hours. At 24 hours the T7-Best 
plasmid was 10-fold higher than the standard in all viruses. Including the 
T7 promoter has the additional advantage of creating a more versatile 
plasmid that could be used in cell free or bacterial expression systems as 
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well. It is unclear why the addition of the T7 promoter amplifies the activity 
of HGL-Best when coupled with viruses such as VC2 and MVA that do not 
express the T7 polymerase. RACE data of mRNA isolated from VC2 and 
vTF7-3 infected cells that were transfected with the T7-Best plasmid show 
the identical sequence in the 5’ UTR as seen with Best alone. This 
indicates that the enhancement happens at transcription, though previous 
studies have shown that the T7 promoter is not a significant VV promoter 
and the T7 sequence does not change the site of transcription initiation.72 
These results lead us to speculate that the T7 promoter works 
synergistically with the HGL-Best mechanism of action to increase mRNA 
production. 
 
	  
47	  
Chapter 3 
CONCLUSIONS 
 
Developing cost effective technologies that can be used to 
generate large quantities of human proteins in their native biological form 
could revolutionize biomedical research.46 Major advantages of our 
technology over existing mammalian expression systems are: (i) a method 
for rapidly producing large quantities of biologically relevant protein in a 
timeframe that can effectively compete with existing E. coli expression 
systems; (ii) a readily available source of viral vectors that are easy to 
engineer and can be used immediately without further processing; (iii) a 
straightforward system that bypasses the need for stably transfected cell 
lines; and (iv) an expression system based on commercially available 
reagents that is compatible with a wide range of cell lines and vaccinia 
viruses, including the modified vaccinia Ankara (MVA) strain, which is non-
pathogenic in humans and approved for use under standard biosafety 
level 1 conditions.73 We suggest that this technology could accelerate 
protein production in mammalian cells for routine laboratory analysis. 
In addition to improving protein yields from VV expression systems, 
HGL-Best also has the potential to advance VV based vaccine 
development. Due to thorough characterization and its success in 
eradicating smallpox, VV is an attractive candidate for the development of 
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recombinant, live vaccines.63 Attenuated strains that are safer than the 
wild type VV have been developed for this purpose but unfortunately, 
these strains tend to make less effective vaccines.65 Incorporating HGL-
Best into these genetically modified strains could boost antigen expression 
levels and help to generate the immune response necessary for a 
successful vaccination. 
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